Cash, Cash Equivalents, Restricted Cash, and Investments: As of September 30 , the Company had cash, cash equivalents, restricted cash, and investments of $199.5M, compared to $113.4M as of December 31.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMEA:
- Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
- Biomea Fusion announces first patient dosed in COVALENT-103 trial
- JPMorgan biotech analysts hold an analyst/industry conference call
- Biomea Fusion announces FDA clearance of IND application for BMF-219